H Umamahesvari
Abstract
Taxanes are highly active chemotherapeutic agents in the treatment of early-stage and metastatic breast cancer. Taxanes signify an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic molecular status. Novel formulations have been developed to improve effectiveness and decrease toxicity associated with these cytotoxic agents. To overcome the poor water solubility of Taxanes , lipid-based solvents have been used as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-bound, 130- nm particle formulation of paclitaxel, free from any kind of solvent apart from this, technological parameters such as polymer concentration and polymer composition have significant influences on characterization of nanoparticles. These parameters lead to variations in particle size and surface charge of nanoparticles which are very important parameters on their transmembranal passage and tissue targeting properties. The encapsulation of paclitaxel in biodegradable and non-toxic nanodelivery systems can protect the drug from degradation during circulation and inturn protect the body from toxic side effects of the drug thereby lowering its toxicity, increasing its circulation halflife, exhibiting improved pharmacokinetic profiles, and demonstrating better patient compliance. In this review we two types of developed paclitaxel nano-delivery systems such as polymer based and albumin based will be compared for the best choice of drug delivery system of nanoparticels.